Trump's Drug Pricing Deals Leave Key Questions Unanswered — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Trump administration announced on Monday a second group of pharmaceutical companies pledged to lower drug prices to levels comparable to those in other nations
- President Trump has touted the deals from the White House as one of the most important breakthroughs in health care, yet the agreements' details aren't public
- A key unresolved question is whether all companies in the second wave would avoid tariffs or otherwise mandatory Medicare drug pricing pilot programs
- The White House did not respond to requests for comment about these questions
Why it matters: The opacity around the deals means patients, payers, and investors can't verify whether these voluntary pledges translate into lower out-of-pocket drug costs or merely shield participating companies from tariffs and mandatory Medicare pricing changes—raising the stakes on whether 'breakthrough' is policy or theater.
Ask SkimNews
